MwanzoSTRO • NASDAQ
add
Sutro Biopharma Inc
$ 1.79
Baada ya Saa za Kazi:(0.49%)-0.0087
$ 1.78
Imefungwa: 13 Jan, 16:30:00 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 1.85
Bei za siku
$ 1.71 - $ 1.84
Bei za mwaka
$ 1.70 - $ 6.13
Thamani ya kampuni katika soko
147.60M USD
Wastani wa hisa zilizouzwa
1.22M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 8.52M | -49.66% |
Matumizi ya uendeshaji wa biashara | 14.33M | -6.14% |
Mapato halisi | -48.79M | 1.01% |
Kiwango cha faida halisi | -572.62 | -96.63% |
Mapato kwa kila hisa | -0.50 | 38.49% |
EBITDA | -66.12M | -56.40% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 388.25M | 9.32% |
Jumla ya mali | 451.83M | 4.66% |
Jumla ya dhima | 340.61M | 6.65% |
Jumla ya hisa | 111.22M | — |
hisa zilizosalia | 82.46M | — |
Uwiano wa bei na thamani | 1.37 | — |
Faida inayotokana na mali | -36.09% | — |
Faida inayotokana mtaji | -107.88% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -48.79M | 1.01% |
Pesa kutokana na shughuli | -64.52M | -92.57% |
Pesa kutokana na uwekezaji | 147.29M | 229.18% |
Pesa kutokana na ufadhili | 1.02M | 117.72% |
Mabadiliko halisi ya pesa taslimu | 83.79M | 154.67% |
Mtiririko huru wa pesa | -39.84M | -81.30% |
Kuhusu
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
Ilianzishwa
2003
Makao Makuu
Tovuti
Wafanyakazi
306
